Navigation Links
Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
Date:3/13/2008

cies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the ability of Boston Scientific Corporation to successfully manufacture, market and sell their paclitaxel-eluting coronary stent products; the continued availability of capital to finance our activities; our ability to achieve the financial benefits expected as a result of the ac
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
2. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
6. Angiotech and Symphony Medical Announce Licensing Agreement
7. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech to participate in Bank of America 2007 Credit Conference
11. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... MIAMI , Aug. 26, 2015  The ... at the University of Miami Miller School of ... its clinical trial to test for the first ... was successfully completed.  This FDA approved Phase I/II ... islet transplantation and is an important first step ...
(Date:8/26/2015)... 26, 2015 Israel Proves Its Place in ... st place  Wayerz comes in 5 th ... by venture capital fund JVP, with Chinese consulting firm ... China , Israel , ... Impressive achievement for the Israeli representatives in the final round ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... Third Quarter 2008 GAAP Earnings Per Share were $1.09, an Increase from ... Per Share of $0.18, Full Year Revenue Guidance Raised from $14.6 Billion ... $14.9 Billion ... to $4.45 - $4.55, THOUSAND OAKS, Calif., Oct. 22 Amgen (Nasdaq:,AMGN) ...
... the leader in,automated proofreading solutions for the pharmaceutical ... pharmaceutical companies have selected Global,Vision to help them ... from,occurring in their packaging process. The integration of ... quality issues and,costs, along with speeding up product ...
... antagonist now approved in single-use ... ... US, Inc. today,announced that the U.S. Food and Drug Administration ... hydrochloride,injection) Premixed in 5% Dextrose. Discovered and developed by Astellas,Vaprisol, ...
Cached Biology Technology:Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 2Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 3Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 4Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 5Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 6Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 7Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 8Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 9Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 10Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 11Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 12Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 13Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 14Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 15Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 16Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 17Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 18Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 19Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 20Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 21Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 22Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 23Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 24Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 3FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 4
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... a cellular trigger that normally regulates replenishment of ... in mice. Removing the abnormal stimulation causes the ... a possible treatment for the lethal, aggressive brain ... Erica L. Jackson, of the University of California, ...
... published by BioMed Central, the open access publisher, received ... in the top 10 of their 2005 Journal Citation ... Factor exceeding 3.00, open access journals are confirmed as ... Central's flagship title covering biology in the post-genomic era, ...
... scientists working at the epicenter of the AIDS epidemic ... virus (HIV) "exhausts" killer T cells that would otherwise ... simply "turn off" fully functional T cells by flipping ... studies, however, the scientists showed that they could reinvigorate ...
Cached Biology News:Possible birthplace of malignant brain tumors identified 2Impressive new Impact Factors for BioMed Central's open-access journals 2How HIV 'exhausts' killer T cells 2How HIV 'exhausts' killer T cells 3How HIV 'exhausts' killer T cells 4